Navigation Links
BD Announces Acquisition of Cytopeia
Date:5/13/2008

Expands Portfolio of Advanced Flow Cytometry Platforms

FRANKLIN LAKES, N.J., May 13 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has acquired all of the outstanding stock of Cytopeia, a privately held Washington corporation based in Seattle that develops and markets advanced flow cytometry cell sorting instruments.

Financial terms of this transaction were not disclosed. The acquisition is not expected to have a material impact on BD's fiscal year 2008 earnings.

"This strategic acquisition brings new technologies and capabilities that will enhance BD's ability to address growing customer needs in advanced applications, such as cell therapy research," said William A. Kozy, BD Executive Vice President. "This transaction reflects our commitment to bringing innovative tools to life scientists and will allow us to rapidly enter emerging areas of cell-based research."

Cytopeia's Influx(TM) cell sorter offers BD an open, configurable cell sorting platform that can be fully optimized for researchers' unique application-specific requirements. This high level of choice and control is particularly important for life science research on the leading edge of biomedical discovery. The Influx cell sorter is suited for a range of applications including cell therapy research, stem cell research, drug discovery and development, as well as marine biology. It complements the BD FACSAria(TM) II system -- the platform of choice in research labs around the world for a broad range of immunology cell sorting and multi-color applications.

Through the acquisition, BD gains the scientific leadership and insights of Dr. Ger van den Engh, a renowned innovator in flow cytometry. Dr. van den Engh will join BD Biosciences, a segment of BD, as Vice President, Advanced Cytometry. In this role, he will manage continuing research and technology development activities in Seattle.

"In addition to access to BD Biosciences' unparalleled portfolio of cellular research tools, Cytopeia's customers will benefit from our high- quality manufacturing and global customer support capabilities," Kozy said.

BD Biosciences is a pioneer and leader in the field of flow cytometry for cellular analysis. BD manufactured the first BD FACS(TM) (fluorescence- activated cell sorting) system in 1973. Today, BD Biosciences offers broad portfolios of research and clinical flow cytometry platforms and reagents designed for cellular characterization and sorting, as well as tools to aid in drug discovery and the growth of living cells and tissue.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statement to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Chindex International Announces Shelf Registration, Related Strategy and Guidance
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
4. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
9. Aton Pharma Announces Distribution Partnership in Brazil
10. China Medicine Announces Solid First Quarter 2008 Results
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):